| Trial ID: | L2619 |
| Source ID: | NCT01847144
|
| Associated Drug: |
Gliclazide 80mg Od
|
| Title: |
MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes
|
| Acronym: |
Mastermind
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Gliclazide 80mg OD|DRUG: Sitagliptin 100mg OD
|
| Outcome Measures: |
Primary: Change in fasting glucose, Change in fasting glucose from 0 to 4 weeks post treatment change., 4 weeks post treatment change | Secondary: Additional changes in biochemical results, Secondary outcome measures will include change in glycosylated albumin, HbA1c, home glucose day profile and mixed meal area under the curve glucose, 4 weeks
|
| Sponsor/Collaborators: |
Sponsor: Royal Devon and Exeter NHS Foundation Trust | Collaborators: University of Exeter
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
143
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2013-04
|
| Completion Date: |
2015-02
|
| Results First Posted: |
|
| Last Update Posted: |
2018-06-21
|
| Locations: |
NIHR Exeter Clinical Research Facility, Royal Devon & Exeter NHS Foundation Trust, Exeter, Devon, EX2 5DW, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT01847144
|
